Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous [5%, 10%, and Other Concentrations] and Subcutaneous [16.5%, 20%, and Other Concentrations])

Portland, OR -- (SBWire) -- 10/26/2017 --Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously in the treatment of various deficiencies. The global immunoglobulin was valued at $8,374 million in 2016, and is projected to reach $13,619 million by 2023, registering a CAGR of 7.3% from 2017 to 2023.

The report segments the global immunoglobulin market based on application, product type, mode of delivery, and concentration. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Hypogammaglobulinemia and CIDP held dominant market shares in 2016 due to the large patient population and unavailability of effective alternatives to immunoglobulin treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. Intravenous mode of delivery is further categorized into 5%, 10%, and other concentration. Subcutaneous mode of delivery is further classified into 16.5%, 20%, and other concentration.

Request for Sample Copy@ https://www.researchbeam.com/immunoglobulin-market/request-sample

Immunoglobulin market is driven by the increase in prevalence of chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia, and rise in use of immunoglobulins to treat Guillainââ'¬ÂBarre syndrome, inflammatory myopathies, specific antibody deficiency, and others. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin. Increase in geriatric population and hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) are the other key factors that contribute to the market growth. In addition, the market is restrained by the stringent government regulations, high cost of therapy, and high risk of side effects associated with the use of immunoglobulin.

For Purchase Enquiry@ https://www.researchbeam.com/immunoglobulin-market/enquire-about-report

KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- Market estimations are based on comprehensive analysis of the key developments in the industry.
- The global market is comprehensively analyzed with respect to products type, application, mode of delivery, and geography.
- In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.